The landscape of personal health management is undergoing a profound transformation, with blood panel diagnostics, once exclusively the domain of medical practitioners, rapidly emerging as a cornerstone of the burgeoning wellness industry. This paradigm shift underscores a broader trend towards proactive health, personalized insights, and direct-to-consumer (DTC) access to sophisticated medical data. A recent and significant development in this evolving market is Function Health’s acquisition of Getlabs, a strategic move poised to streamline at-home diagnostic testing for a growing consumer base eager to unlock their unique biological blueprints.<\/p>\n
Function Health’s Strategic Acquisition of Getlabs: Revolutionizing Access to Personal Health Data<\/strong><\/p>\n Last week, Function Health, a telehealth platform launched in 2022 with a mission to provide direct-to-consumer medical testing, announced its acquisition of Getlabs. This pivotal move signals a deeper integration within the wellness diagnostics sector, aiming to enhance the accessibility and convenience of lab testing for Function Health’s substantial membership of 500,000 individuals. Getlabs, established in 2021, operates as a mobile lab testing network, deploying certified phlebotomists directly to clients’ homes or offices. These skilled professionals collect a range of samples\u2014including blood, urine, stool, or saliva\u2014which are then expeditiously delivered to partner laboratories for processing.<\/p>\n Function Health\u2019s platform specializes in identifying nutritional deficiencies, hormone irregularities, and other critical biomarkers that, according to the company, are frequently overlooked in conventional medical visits. The acquisition of Getlabs directly addresses a primary logistical hurdle in direct-to-consumer diagnostics: the often-inconvenient process of sample collection. By integrating Getlabs’ mobile phlebotomy services, Function Health aims to make the collection of lab samples significantly easier and faster for its members, thereby removing a key barrier to regular health monitoring.<\/p>\n Dr. Mark Hyman, co-founder and chief medical officer of Function Health, articulated the company’s foundational philosophy in a February interview with Glossy: "Ultimately, you can’t really define your health without knowing your personal health data. And that’s really where Function comes in. It allows you to understand what’s going on with your biology in real time, to put your biology online, [and] to have it really give you insights about what’s happening." This statement encapsulates the core value proposition of Function Health and indeed, much of the personalized wellness movement: empowering individuals with granular, real-time data about their physiological state.<\/p>\n Prior to the Getlabs acquisition, Function Health maintained an in-person partnership with Quest Diagnostics, a titan in the labs business boasting over 6,000 locations across the United States. This existing partnership will continue, providing Function Health users with a dual-option approach to sample collection. Members can now choose between visiting a Quest Diagnostics facility or opting for the convenience of Getlabs’ at-home service, with all samples collected by Getlabs still being delivered to Quest for analysis. Function Health’s membership model, priced at $365 per year, includes one round of blood test labs, with additional tests available \u00e0 la carte, offering flexibility and customization to users.<\/p>\n A Look at Getlabs’ Journey and the Competitive Landscape<\/strong><\/p>\n Getlabs’ trajectory highlights the rapid growth and investor confidence in the mobile diagnostics sector. The company launched in 2021 with an initial $3 million seed round of funding led by Pivot North Capital. This was followed by a substantial $20 million Series A funding round in 2022, spearheaded by Emerson Collective and the Minderoo Foundation, underscoring significant institutional belief in its model. Founded by Kyle Michelson, who served as CEO until June 2025, Getlabs saw a leadership transition with Claire Hough, former CTO at Carbon Health, assuming the chief executive role. This leadership change, even amidst acquisition, points to the dynamic nature of high-growth tech-driven health companies.<\/p>\n The broader market for blood panel diagnostics is experiencing an explosive growth trajectory. According to market research firm Grand View Research, the global blood panel diagnostics market, valued at an estimated $94 billion in 2024, is projected to surge past $160 billion by 2030. This robust expansion is characterized by a compound annual growth rate (CAGR) of 8.83%, indicating a sustained and significant increase in demand. North America currently dominates this market, accounting for a substantial 44% share, reflecting high consumer awareness, advanced healthcare infrastructure, and a strong uptake of wellness-focused technologies.<\/p>\n The "Why" Behind the Boom: Consumer Demand and Preventative Health<\/strong><\/p>\n The surge in demand for direct-to-consumer blood panels is driven by several intertwined factors. Consumers are increasingly proactive about their health, moving away from a purely reactive, illness-centric model of care towards preventative and personalized wellness. The digital age has fostered a culture of data accessibility and self-optimization, where individuals seek to understand and control various aspects of their lives, including their health metrics.<\/p>\n Traditional medical visits often focus on symptom-driven diagnostics, potentially overlooking subclinical deficiencies or early indicators of health issues. Function Health and similar platforms aim to fill this gap by offering comprehensive panels that delve into areas like nutritional status, hormone balance, and inflammation markers, which are critical for optimizing well-being and preventing chronic disease. As Dr. Hyman noted, many people "are walking around feeling like crap, [and] they just don’t know why." Access to detailed blood test results can be revelatory, as individuals discover deficiencies like critically low vitamin D levels, which can manifest as fatigue, muscle pain, and depression. This realization often empowers them to make informed lifestyle changes or seek targeted interventions.<\/p>\n Common Diagnostics and Unmet Needs<\/strong><\/p>\n Grand View Research identifies several common reasons for individuals to seek blood panels. Testing for blood sugar levels, including A1C and glucose, tops the list, followed closely by cholesterol testing (LDL or lipid panels) and COVID-19 tests. Kidney, thyroid, and prostate testing also rank highly. Interestingly, among nutrient tests, only vitamin D testing made it into the top ten. This aligns with a significant finding from a 2010 study at Oregon State University, which indicated that an alarming 95% of U.S. adults are deficient in vitamin D. This widespread deficiency has, in turn, fueled a boom in vitamin D supplement sales and new supplement brand launches.<\/p>\n However, the proliferation of supplements has also brought warnings from health experts against "supplement stacking" without a clear understanding of individual nutrient deficiencies, which can only be accurately determined through blood panels. This highlights the crucial role of diagnostics in guiding informed supplementation and preventing both over-supplementation and continued deficiency.<\/p>\n A Crowded and Innovating Market: Key Players and Emerging Trends<\/strong><\/p>\n The blood panel market is a dynamic ecosystem populated by established giants and innovative newcomers. Leading the pack are traditional lab services like Quest Diagnostics, alongside at-home testing and glucose monitoring innovators such as Abbott and Roche Diagnostics. These companies offer cutting-edge solutions that cater to both clinical and consumer needs.<\/p>\n Emerging players are also making significant inroads. Guardant Health, which reported $281 million in revenue in Q4 2025, and Bio-Rad Laboratories, generating $693 million in the same quarter, are two California-headquartered companies offering various at-home lab tests and contributing to the market’s rapid evolution.<\/p>\n Beyond dedicated diagnostic companies, the trend has permeated adjacent sectors within the wellness industry. Longevity clinics, a burgeoning segment focused on extending healthy lifespans, have integrated blood panels as a core offering. Examples include Love Life, launched in 2024 by a former Whole Foods co-founder, with memberships starting at $650 per month, and Miora, the new longevity clinic from luxury gym Life Time Fitness, which offers a diagnostics package including consultation, blood work, and a wellness protocol for $299. These clinics leverage comprehensive diagnostics to create highly personalized health and anti-aging strategies.<\/p>\n Even health data tracking companies, which traditionally focused on wearables, are now incorporating blood panels into their offerings. Users of popular wrist trackers like Whoop and Oura rings can purchase blood tests directly through their respective apps to check a bespoke combination of biomarkers. Both brands, which launched these partnerships in September and October, collaborate with Quest Diagnostics for test facilitation. Oura charges $99 per test, while Whoop integrates one test into its annual membership, which starts at $199. This integration demonstrates a clear recognition that wearable data, while valuable, gains deeper context when combined with internal biological markers.<\/p>\n Furthermore, platforms specifically designed around lab test analysis are gaining traction. Superpower, for instance, streamlines the payment, scheduling, and analysis of tests conducted at Quest Diagnostics locations. The company secured a substantial $50 million in Series A funding last year, led by Forerunner Ventures, highlighting investor confidence in the analysis and interpretation layer of the diagnostics market. Levels Health, co-founded in 2019 by Dr. Casey Means, (who is also President Donald Trump\u2019s current nominee for U.S. Attorney General), utilizes continuous glucose monitoring devices to track blood sugar and other biomarkers, offering another dimension of real-time biological insight.<\/p>\n The Drive Towards Vertical Integration and At-Home Collection<\/strong><\/p>\n Function Health’s acquisition of Getlabs is indicative of a broader industry trend towards vertical integration, as health data companies seek to control more of the diagnostic value chain. This strategy aims to enhance efficiency, reduce costs, and improve the user experience by bringing more services in-house or through exclusive partnerships.<\/p>\n A prime example of this vertical integration and innovation in at-home collection comes from Hims & Hers, a leading telehealth platform. In early 2025, the company announced ambitious plans to introduce at-home lab testing through two strategic acquisitions. It acquired New Jersey-based Trybe Labs, known for its FDA-approved, minimally invasive at-home blood-collection device that allows users to self-collect blood samples and mail them to a lab. Concurrently, Hims & Hers also announced plans to acquire YourBio, a Boston-based manufacturer of its patented TAP device, which utilizes a proprietary Halo microneedle system for comfortable and efficient at-home blood collection. These acquisitions signify a strong push towards making diagnostics even more convenient and less invasive, potentially democratizing access to personal health data on an unprecedented scale.<\/p>\n Broader Wellness Market Trends<\/strong><\/p>\n Beyond blood panel diagnostics, the wellness industry continues its robust expansion across various sectors:<\/p>\n Challenges and the Road Ahead<\/strong><\/p>\n While the growth in personalized diagnostics offers immense potential for improved health outcomes, it also presents challenges. Regulatory oversight, particularly concerning the accuracy of at-home devices and the interpretation of complex biomarker data, remains a critical area. Ensuring data privacy and security in a rapidly expanding digital health ecosystem is paramount. Furthermore, the ethical implications of direct-to-consumer genetic and health data, including potential for over-testing or misinterpretation without professional medical guidance, require careful consideration.<\/p>\n Despite these complexities, the trajectory is clear: personalized health data, anchored by accessible blood panel diagnostics, is becoming an indispensable tool for consumers seeking to take a more active role in managing their well-being. The acquisition of Getlabs by Function Health is not merely a corporate transaction; it is a testament to the accelerating pace of innovation and consumer-centricity defining the future of healthcare. As technology continues to advance and consumer awareness deepens, the "big business" of blood panels is set to redefine how individuals understand, monitor, and ultimately optimize their health.<\/p>\n","protected":false},"excerpt":{"rendered":" The landscape of personal health management is undergoing a profound transformation, with blood panel diagnostics, once exclusively the domain of medical practitioners, rapidly emerging as a cornerstone of the burgeoning wellness industry. This paradigm shift underscores a broader trend towards proactive health, personalized insights, and direct-to-consumer (DTC) access to sophisticated medical data. A recent and …<\/p>\n","protected":false},"author":13,"featured_media":5301,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[131],"tags":[624,134,491,141,622,133,626,132,623,625,447,618,629,620,135,627,621,630,628,136],"class_list":["post-5302","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fashion-technology-and-innovation","tag-acquires","tag-ai","tag-amidst","tag-blood","tag-boom","tag-e-commerce","tag-explosive","tag-fashiontech","tag-function","tag-getlabs","tag-growth","tag-health","tag-healthcare","tag-industry","tag-innovation","tag-market","tag-panel","tag-paradigms","tag-shifting","tag-wellness"],"_links":{"self":[{"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/posts\/5302","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/comments?post=5302"}],"version-history":[{"count":0,"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/posts\/5302\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/media\/5301"}],"wp:attachment":[{"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/media?parent=5302"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/categories?post=5302"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/fashionstudio.info\/index.php\/wp-json\/wp\/v2\/tags?post=5302"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n